Company news
Compass Therapeutics, Inc. news in 2022
Compass Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Compass Therapeutics Announces Presentation of Updated Results from the Ongoing Phase 2 study of CTX-009 in Biliary Tract Cancer (BTC) at the 2023 ASCO GI Cancers Symposium January 19-21
December 14, 2022
Compass Therapeutics Announces First Patient Dosed in the Phase 1b CTX-471 Combination Trial with KEYTRUDA® (pembrolizumab)
November 30, 2022
Compass Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
November 21, 2022
Compass Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 8, 2022
Compass Therapeutics to Present at Upcoming Investment Conferences
November 7, 2022
Compass Therapeutics Announces $80 Million Private Placement
November 1, 2022
Compass Therapeutics Announces Clinical Collaboration with Merck to Evaluate CTX-471 in Combination with KEYTRUDA® (pembrolizumab)
October 10, 2022
Compass Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
September 8, 2022
Compass Therapeutics to Present at the 13th Annual Wedbush PacGrow Healthcare Conference
August 1, 2022
Compass Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
July 31, 2022
Compass Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference
May 30, 2022
Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference
May 22, 2022
Compass Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
May 8, 2022
Compass Therapeutics to Present at the Bank of America Securities 2022 Healthcare Conference on Thursday, May 12, 2022 at 11: 20 a.m. PT
May 4, 2022
Compass Therapeutics Reports Positive Interim Phase 2 Data of CTX-009 in Combination with Paclitaxel in Biliary Tract Cancers
May 3, 2022
Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009
May 2, 2022
Compass Therapeutics Announces Appointment of Two New Directors to its Board
April 25, 2022
Compass Therapeutics Presents Data on CTX-8371, a Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting
April 7, 2022
Compass Therapeutics Announces Presentation on CTX-8371, A Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting in New Orleans
March 29, 2022
Compass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 20, 2022
Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)
January 19, 2022
Compass Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 6, 2022
Decks in 2022
- Investor Presentation (May 2022)
Investor deck · 36 slides · May 4, 2022